CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin in August 1997 and is headquartered in Princeton, NJ.
Sector:
Health Technology
Industry:
Medical Specialties
Employees:
149
Frequently Asked Questions
What is Market Cap of Cytosorbents Corp?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Cytosorbents Corp market cap is $53.36M.
What is the 52-week high for Cytosorbents Corp?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Cytosorbents Corp 52 week high is $1.61 as of October 25, 2025.
What is the 52-week low for Cytosorbents Corp?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Cytosorbents Corp 52 week low is $0.7101 as of October 25, 2025.
What is the PE ratio of Cytosorbents Corp?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Cytosorbents Corp’s P/E ratio is -4.66.
What is the Price-to-Book ratio of Cytosorbents Corp?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Cytosorbents Corp P/B ratio is 4.5944.
What is the 50-day moving average of Cytosorbents Corp?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Cytosorbents Corp 50-day moving average is $0.9383.
